Indian equity benchmarks staged a sharp intraday recovery on Wednesday after witnessing intense selling pressure earlier in the session, with investors selectively buying quality stocks even as broader macroeconomic concerns kept sentiment cautious.
Key Highlights
- Sensex and Nifty recovered sharply from intraday lows despite broader concerns over macroeconomic uncertainty.
- Rupee hit record low while pharma stocks surged, supported by export gains and defensive buying.
The BSE Sensex was last trading 127.74 points higher at 75,328.59, while the NSE Nifty50 gained 50.65 points to 23,668.65, recovering nearly 800 points and 270 points respectively from their day’s lows. The rebound reflected resilience in domestic equities despite continued pressure from a weakening rupee, elevated bond yields, and global geopolitical uncertainty.
Market experts advised investors to remain disciplined and avoid aggressive positioning in the current volatile environment.
Abhishek Basumallick, Co-founder and Fund Manager at Shree Rama Managers, urged investors to remain conservative."Avoid going all in, even if you are investing with a long-term perspective. Maintain a staggered approach or consider investing through the SIP route. This is not a very conducive market for taking concentrated positions," he said.
Echoing caution, Kranthi Bathini, Equity Strategist at WealthMills Securities, recommended a tactical approach. "The current market environment favours a buy-on-dips and sell-on-rallies strategy," he noted.
Meanwhile, VK Vijayakumar, Chief Investment Strategist at Geojit Investments, highlighted macroeconomic headwinds weighing on sentiment. "FY27 GDP growth could moderate to around 6%, while inflation may remain elevated near 5.5%. Markets appear to have largely discounted this. Investors should prioritise value stocks available at fair valuations. Patience remains key in these testing times," he said.
Also Read: Indian Markets Rebound After 1,000-Point Crash, Sensex Recovers
Pharma Stocks Emerge as Market Leaders
A standout feature of Wednesday’s trade was the strong performance of India’s pharmaceutical sector.
The Nifty Pharma index touched a fresh record high, supported by sustained investor interest in export-oriented businesses and defensive sectors amid broader market volatility.
Gaurav Sharma of Globe Capital said pharma has consistently attracted buying interest over the past month. "Most pharma companies have reported healthy quarterly earnings. A depreciating rupee directly benefits export-driven sectors like pharmaceuticals and IT, improving earnings visibility," he said.
Kranthi Bathini also linked the sector’s rally to currency tailwinds and strong medium-term growth prospects. "Pharma and healthcare stocks remain attractive for medium- to long-term investors," he added.
Apart from rupee depreciation, rising global demand for generic weight-loss drugs and expanding export opportunities have further strengthened sentiment toward Indian pharmaceutical companies.
Rupee Hits Fresh Record Low
Despite the equity rebound, the Indian rupee weakened to a fresh record low of 96.88 against the US dollar, raising concerns over imported inflation and pressure on corporate margins.
The rupee’s decline reflects broader global risk aversion, persistent foreign institutional investor selling, elevated crude oil prices, and higher US bond yields.
While volatility is likely to persist, analysts believe selective buying in fundamentally strong sectors such as pharma and healthcare could continue to support Indian markets in the near term.
